US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco S&P SmallCap Health Care ETF

54.70

-0.1760-0.32%

Volume:2K

Turnover:90.06K

Market Cap:184.35M

PE:- -

High:54.70

Open:54.70

Low:54.70

Close:54.88

52wk High:56.45

52wk Low:39.08

Shares:3.37M

Float Shares:3.37M

Volume Ratio:0.19

T/O Rate:0.05%

Dividend:0.00

Dividend Rate:0.01%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

8 ‘trendsetter’ stocks for world’s top mega-trends: Jon Erlichman

The Race to Come up with the Next Big Sleep Drug

Corcept Therapeutics (CORT) Stock Could Be Undervalued Despite Mixed Broader Checks

Simply Wall St.

Takeda Wins First-in-Class U.S. Approval for Orexin Therapy in Narcolepsy Type 1

Corcept Chief Accounting & Technology Officer Joseph Douglas Lyon Disposes of 1,540 Common Shares Worth $175,806.40

Arcutis Q2 Revenue Rises on Demand for Zoryve, Lifts 2026 Sales Outlook

United Therapeutics Q2 Revenue Misses Estimates on Ebulized Tyvaso Weakness

Ultragenyx Q2 Revenue Rises 28% to Record High, Net Loss Narrows

Alkermes EVP, CLO David Joseph Gaffin Sells 2,034 Shares for $98,821.72

Corcept CFO Atabak Mokari Sells 79,000 Shares Worth $8.95 Million

Fresenius announces FDA approval of rituximab biosimilar

ClearPoint Neuro Q2 Revenue Rises 18% but Misses Estimates

GeneDx Q2 Revenue Beats Analyst Estimates

Alkermes Amends 8-K to Disclose CEO Blair Jackson Pay Package Including $5 Million Equity Award

Krystal Biotech Down Nearly 12%, on Pace for Largest Percent Decrease Since August 2025

Wall Street Analysts Are Bullish on Top Healthcare Picks

Wall Street Analysts Are Bullish on Top Healthcare Picks

Krystal Biotech Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Design Therapeutics Q2 Net Loss Narrower than Expected

Ocular Therapeutix Q2 Product Revenue Flat, Net Loss Widens on Higher Spending

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/PSCH/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PSCH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSCH\",,,,,undefined,":{"symbol":"PSCH","market":"US","secType":"STK","nameCN":"Invesco S&P SmallCap Health Care ETF","latestPrice":54.704,"timestamp":1788453076529,"preClose":54.88,"halted":0,"volume":1644,"delay":0,"changeRate":-0.00320699708454814,"floatShares":3370000,"shares":3370000,"eps":0,"marketStatus":"Trading","change":-0.176,"latestTime":"09-03 12:38:21 EDT","open":54.7009,"high":54.704,"low":54.7009,"amount":90055.470948,"amplitude":0.000056,"askPrice":54.93,"askSize":400,"bidPrice":54.85,"bidSize":800,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788465600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":54.88,"sharesOutstanding":3220000,"nav":54.508,"aum":183691960,"dividendRate":0.000055,"bidAskSpread":0.001979,"postHourTrading":{"tag":"盘后","latestPrice":54.88,"preClose":54.88,"latestTime":"16:15 EDT","volume":10,"amount":548.8,"timestamp":1788380100261,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.19229,"impliedVol":0.1092,"impliedVolPercentile":0.6825},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSCH\",,,,,undefined,":{"symbol":"PSCH","floatShares":3370000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.19229,"shares":3370000,"dividePrice":0.003,"high":54.704,"amplitude":0.000056,"preClose":54.88,"low":54.7009,"week52Low":39.08,"pbRate":"--","week52High":56.454,"institutionHeld":0,"latestPrice":54.704,"committee":0.333333,"eps":0,"divideRate":0.000055,"volume":1644,"delay":0,"ttmEps":0,"open":54.7009,"prevYearClose":44.0553,"prevWeekClose":54.65,"prevMonthClose":54.61,"prevQuarterClose":52.3666,"fiveDayClose":55.44,"twentyDayClose":54.01,"sixtyDayClose":47.3417},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSCH\",params:#limit:5,,,undefined,":[{"date":"2026-03-23","symbol":"PSCH","amount":0.00033,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-09-22","symbol":"PSCH","amount":0.00259,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"PSCH","amount":0.00199,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-24","symbol":"PSCH","amount":0.01419,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-24","defaultRemindTime":1742823000000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-24","currency":"USD","dateTimestamp":1742788800000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSCH","amount":0.01801,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-27","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSCH\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-30","value":0.01949,"currency":"USD"},{"executeDate":"2018-09-24","recordDate":"2018-09-25","paymentDate":"2018-09-28","value":0.00522,"currency":"USD"},{"executeDate":"2022-03-31","recordDate":null,"paymentDate":"2022-03-31","value":3,"currency":"USD"},{"executeDate":"2023-12-18","recordDate":"2023-12-19","paymentDate":"2023-12-22","value":0.00448,"currency":"USD"},{"executeDate":"2024-03-18","recordDate":"2024-03-19","paymentDate":"2024-03-22","value":0.03613,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSCH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSCH\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657646644","title":"8 ‘trendsetter’ stocks for world’s top mega-trends: Jon Erlichman","url":"https://stock-news.laohu8.com/highlight/detail?id=2657646644","media":"Bloomberg","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657646644?lang=en_us&edition=fundamental","pubTime":"2026-08-07 17:00","pubTimestamp":1786093200,"startTime":"0","endTime":"0","summary":"In the latest episode of Ticker Take, I spoke with Matt Orton of Raymond James Investment Management about that top-down approach, and the stocks he thinks fit it best.","market":"us","thumbnail":"https://www.bnnbloomberg.ca/resizer/v2/ALRJGLKISQ5YQHT52J5GP2R3AQ.jpg?smart=true&auth=3cd1da2341d3279ac2053fa569f000b8d932710ca1ee4a201f166838db8d2c6d&width=500&height=333","type":0,"news_type":0,"thumbnails":["https://www.bnnbloomberg.ca/resizer/v2/ALRJGLKISQ5YQHT52J5GP2R3AQ.jpg?smart=true&auth=3cd1da2341d3279ac2053fa569f000b8d932710ca1ee4a201f166838db8d2c6d&width=500&height=333"],"rights":{"source":"bnn_bloomberg_highlight","url":"https://www.bnnbloomberg.ca/ticker-take/2026/08/07/8-trendsetter-stocks-for-worlds-top-mega-trends-jon-erlichman/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bnnbloomberg.ca/ticker-take/2026/08/07/8-trendsetter-stocks-for-worlds-top-mega-trends-jon-erlichman/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bnn_bloomberg_highlight","symbols":["LU2108987350.USD","IE00BFSS8Q28.SGD","LU0320765059.SGD","LU0787776722.HKD","SOXX","WDNA","LU0889565833.HKD","MHIP","IE00BJLML261.HKD","LU0466842654.USD","LU0316494557.USD","MEDX","LU1282649810.SGD","LU2111349929.HKD","LU2458330169.SGD","IE000M9KFDE8.USD","XNTK","LU0082616367.USD","LLY","LU2168564222.USD","BK4554","TTEQ","LU0109391861.USD","IYH","LU2247934214.USD","ILDR","LU0210536198.USD","IE00BQXX3D17.EUR","IE00B7KXQ091.USD","LU0384037296.USD","LU0689472784.USD","KNOW","LU0965509010.AUD","SG9999015986.USD","IE00B1BXHZ80.USD","IE00BFXG0V08.USD","LU0266013472.USD","BK4591","BK4187","FTXL","LU1551013425.SGD","LU1571399168.USD","LU0109392836.USD","SG9999015952.SGD","IE00BKDWB100.SGD","TMED","SG9999014906.USD","BK4553","SGXZ31699556.SGD","AVSE","LU1861215975.USD","IE00BFTCPJ56.SGD","HVAC","LU1861220033.SGD","IE00BK4W5L77.USD","LU1267930490.SGD","LU1868838027.USD","LU2237443978.SGD","LU0211327993.USD","LU2746668461.USD","MUD","LU1282649067.USD","LU1814569148.SGD","SG9999014914.USD","LU1623119135.USD","LU2133065610.SGD","LU2087625088.SGD","LU1280957306.USD","CGNG","LU0256863811.USD","LU2491050154.USD","SPWO","SHOC","LU2750360641.GBP","LLYX","LU0203201768.USD","SG9999001176.SGD","LU2023250504.SGD","IE00B4JS1V06.HKD","BAI","CGDG","IE00BK4W5M84.HKD","LU0130102774.USD","SG9999018857.SGD","BK4575","LU1145028129.USD","LU1674673691.USD","CGIC","BK4527","LU0154236417.USD","FSPC","LU1974910355.USD","LU1093756168.USD","IE00BJJMRY28.SGD","LU2602419157.SGD","CHAT","LU0127658192.USD","LU1023057109.AUD","IE0034235303.USD","LU2089284900.SGD","LU2461242641.AUD","XLK","PSI","LU1868837300.USD","LU1064131342.USD","LU2168564065.EUR","BK4550","BK4526","CHPS","IE00B7SZLL34.SGD","MIC","LU0198837287.USD","SG9999014898.SGD","LU1720051017.SGD","IE0004086264.USD","LU2236285917.USD","SG9999015978.USD","IE0002270589.USD","SG9999013999.USD","LU2106854487.HKD","HRTS","LU0456855351.SGD","IE00BYQQ9H92.USD","LU0058720904.USD","LU2048586759.USD","LU0238689110.USD","LU0323591593.USD","LU0683600562.USD","FXL","TSMG","LU2211815571.USD","LEGR","LU1934455194.USD","TSMU","HBMX","LU1778281490.HKD","TINS","IXN","IE00B19Z3581.USD","LU0432979614.USD","IE0009355771.USD","SG9999000418.SGD","LU2360032135.SGD","LU0823414478.USD","LU2089985449.USD","LU0130517989.USD","LU1037948897.HKD","IE00BN29S564.USD","LU0097036916.USD","AIRR","LU0786609619.USD","TTXU","LU1914381329.SGD","LU1720051108.HKD","LU1989764748.USD","LU2265009873.SGD","LU0353189763.USD","LU2125154935.USD","LU2462157665.USD","SGXZ81514606.USD","LU0980610538.SGD","LU2361045086.USD","LU0471298777.SGD","LU1023059063.AUD","LU2211814178.USD","LU1267930730.SGD","LU1127390331.HKD","LHX","LU1989764664.SGD","LU1989771016.USD","BTSG","BK4566","ELIL","LU0488056044.USD","IE0004445239.USD","LU2491050071.SGD","LU0006306889.USD","LU1267930813.SGD","SG9999015945.SGD","BK4129","IE00B1XK9C88.USD","LU1868836914.USD","LU2294711713.HKD","LU0345770993.USD","EMSF","IE00BQXX3F31.USD","LU2023250330.USD","LU2750360997.AUD","BK4581","LU0359201885.HKD","LU1852331112.SGD","LU0133085943.USD","LU0859254822.USD","LU0689626769.HKD","LU2756315318.SGD","ESIM","IE00B4R5TH58.HKD","SGXZ57979304.SGD","LU0109394709.USD","IE00B5949003.HKD","LU0353189680.USD","LU1211504680.USD","LU2065731478.USD","LU2931357623.SGD","IE00B5TLWC47.USD","LU0640476718.USD","IE00BJT1NW94.SGD","LU0162691827.USD","LU1508157978.USD","LU1506573853.SGD","IE00B2B36J28.USD","GB00BDT5M118.USD","EMC","BK4543","LU0861579265.USD","LU1232071149.USD","LU1804176565.USD","LU2063271972.USD","PTH","LU2290526834.HKD","LU0225283273.USD","LU1988902786.USD","LU1983299246.USD","IE00BLSP4452.SGD","DISK","PSCH","LU2023251221.USD","LU1548497426.USD","LU0541501648.USD","SG9999018865.SGD","BK4503","LU0359201612.USD","LU2746668974.SGD","SG9999004220.SGD","LU0882574055.USD","LU2089984988.USD","WDGF","BK4516","LU0345770308.USD","LU1069344957.HKD","LU1061106388.HKD","LU2324357040.USD","LU2028103732.USD","03145","JDOC","IE0009354923.USD","LU2250418816.HKD","LU1934455863.HKD","LU0820562030.AUD","LU1366333091.USD","LU2054465674.USD","CRDU","LU0792757196.USD","LU2471134952.CNY","LU0203347892.USD","LU2168564495.EUR","LU0348723411.USD","WLDR","LU0158827948.USD","LU0385154629.USD","IE00BLSP4239.USD","BK4007","LU2417539215.USD","LU2168563687.JPY","SOXQ","IE0001KFT4U8.USD","LU2471134796.USD","LU0878005551.USD","UMMA","CRDO","LU1366192091.USD","LU2506951792.HKD","IE00BD6J9T35.USD","BK4505","BK","LU0124676726.USD","BK4135","LU0061475181.USD","LU2458330243.SGD","BK4533","LU0096364046.USD","IE00BZ199S13.USD","LU2237438978.USD","FAI","LU0572939691.SGD","LU0672654240.SGD","BK4585","LU2357305700.SGD","LU2237443465.HKD","MUZ","ADVE","BK4602","LU1037948541.HKD","LU0823416689.USD","LU0354030511.USD","LU0541502299.USD","LU0053671581.USD","LU0174119429.USD","BK4599","LU2360107168.USD","LU1979441026.SGD","LU2361044949.HKD","LU2462591350.SGD","LU0143863784.USD","LU0106261372.USD","LU1815336091.USD","LU0965509283.SGD","SG9999014880.SGD","CANC","LU0820561909.HKD","CWI","VGT","LU0823434583.USD","LU0114720955.EUR","LU0882574139.USD","IHE","LU2361044865.SGD","LU2112291526.USD","LU0417517546.SGD","LU1035775433.USD","IE00BFSS7M15.SGD","LU1868837565.USD","LU0359202008.SGD","LU1917777945.USD","AIFD","RULE","LU2456880835.USD","PJP","LU2213496289.HKD","IE0002141913.USD","LU1699723380.USD","LU2860962120.EUR","LU2360106947.USD","IE00B775H168.HKD","LU0094547139.USD","BK4196","LU1201861249.SGD","LU0471298694.HKD","LLII","LU1989772923.USD","BOBP","CGGO","IETC","LU0211328371.USD","FTXH","LU0157215616.USD","LU0820561818.USD","LU2543165471.USD","LU0889566641.SGD","MUU","IE0004091025.USD","SG9999001176.USD","LU1316542783.SGD","BK4605","TRFK","TSMZ","LU0878004406.USD","MULL","LU0310799852.SGD","LU1674673428.USD","LU2357125470.USD","BK4548","EMM","TSMX","FDTX","AIS","SPTE","LU1291159041.SGD","LU1551013342.USD","LU1868837722.USD","JGRO","IE00BJJMRX11.SGD","IE00BN8TJ469.HKD","IE00BFXG1179.USD","BK4579","THNR","LU1868836591.USD","IE00BHPRN162.USD","IE00B19Z3B42.SGD","BK4612","BK4532","SGXZ99366536.SGD","CHPX","LU1989772840.SGD","TSM","IE00BJJMRZ35.SGD","LU0289739699.SGD","CNEQ","LU2271345857.HKD","SMH","LU0708995401.HKD","LU0965509101.SGD","LU0006061336.USD","LU0648001328.SGD","LU0274383776.USD","CURE","BK4534","LU0943347566.SGD","TEK","ELIS","BLOX","LU0823434740.USD","IE00BWXC8680.SGD","LU0143863198.USD","LU0889565916.HKD","LU2491049909.HKD","LU2264538146.SGD","BK4141","LU2249611893.SGD","LU0642271901.SGD","LU0264606111.USD","LU2237443549.SGD","SG9999001424.SGD","IE00B3M56506.USD","IE0009356076.USD","WUGI","LU0122379950.USD","LU1057294990.SGD","SG9999017495.SGD","MU","LU2552382215.SGD","LU2092937221.SGD","LU2102340556.USD","LU0203345920.USD","EGGY","BK4559","LU2237443622.USD","LU2298321311.HKD","MUYY","LLYZ","LU0572940350.SGD","DRMY","ARTY","FTEC","LU2168564149.EUR","EFIV","LU2468319806.SGD","LU1093756325.SGD","LU1712237335.SGD","LU1934455277.USD","LU1323610961.USD","LU2125154778.USD","IE00BBT3K403.USD","LU0823421416.USD","LU2237443895.HKD","RXL","LU0079474960.USD","LU2552382058.USD","AVEM","BK4588","LU2357627491.SGD","FHLC","LU1803068979.SGD","IE00BSNM7G36.USD","LU1868836757.USD","LU0757428866.USD","XLV","TRUH","LU0964807845.USD","IE00BKPKM429.USD","LU0072461881.USD","AGNG","LU0320765992.SGD","VHT","LU1868837136.USD","GDOC","LU2041044095.USD","LU0314106906.USD","PPH","LU2089283258.USD","LU2756315664.SGD","LU0882747503.HKD","LU2896262040.SGD","MEMX","AIQ","STRL","AVXC","LU0175139822.USD","LU0823414551.USD","LU0234572021.USD","IXJ","ASIA","CORO","LU2471134523.USD","PTF","STSM","LU0256863902.USD","LU0203202063.USD","IE0005OL40V9.USD","LU0289960550.SGD","LU2360106780.USD","BK4512","LU2237443382.USD","LU0477156953.USD","LU0719512351.SGD","MEDI","LU0965508806.USD","LU0158827781.USD","LU2286300806.USD","LU0056508442.USD","LU0354030438.USD","LU2552382132.HKD","TSMY","SGXZ51526630.SGD","IE0004445015.USD","LU0081259029.USD","LU1629891620.HKD","LU2403377893.USD","IE00BQXX3C00.GBP","LU2471134879.HKD","LU2360108059.USD","LU2663582299.SGD","OZEM","USXF","LU0823421333.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651052","title":"The Race to Come up with the Next Big Sleep Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651052","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657651052?lang=en_us&edition=fundamental","pubTime":"2026-08-07 02:30","pubTimestamp":1786041000,"startTime":"0","endTime":"0","summary":"Narcolepsy isn't easy to treat. Existing drugs manage patients' symptoms -- notably excessive daytime sleepiness and difficulty sleeping at night -- rather than the cause. Yet a new type of drug is em","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1623119135.USD","LU0345770308.USD","LU0133085943.USD","LU0316494557.USD","IE00BJLML261.HKD","LU2211815571.USD","LU2324357040.USD","IBRN","LU2168564222.USD","MHIP","LU0097036916.USD","HRTS","LU0198837287.USD","LU0689472784.USD","LU0203202063.USD","SG9999017495.SGD","LU0114720955.EUR","LU0943347566.SGD","LU2168564149.EUR","LU1804176565.USD","LU2456880835.USD","LU2552382132.HKD","IE0005OL40V9.USD","IXJ","LU2896262040.SGD","IE00BJJMRY28.SGD","LU1868836591.USD","LU1868836914.USD","LU0823434740.USD","LU0234572021.USD","LU0238689110.USD","LU1868837136.USD","LU0820562030.AUD","LU0320765992.SGD","LU1814569148.SGD","LU0106261372.USD","SG9999015952.SGD","LU0320765059.SGD","IE00BK4W5M84.HKD","LU0640476718.USD","LU2491050154.USD","ALKS","SGXZ57979304.SGD","FTXH","LU0079474960.USD","IE00B1XK9C88.USD","IE00B7KXQ091.USD","IYH","IE00BN29S564.USD","LU0094547139.USD","AGNG","LU0203201768.USD","LU0672654240.SGD","LU2361044865.SGD","IE00BJT1NW94.SGD","LU0882574139.USD","LU2471134796.USD","LU2087625088.SGD","PJP","TAK","LU2168564495.EUR","LU2552382058.USD","SG9999015978.USD","ILDR","LU2471134523.USD","GDOC","TMED","SG9999018865.SGD","IE00BK4W5L77.USD","ELIL","BK4585","LU1093756168.USD","LU0323591593.USD","LU1093756325.SGD","LU2236285917.USD","LU1291159041.SGD","LU2491049909.HKD","FBT","LU2756315318.SGD","WDNA","LU0289739699.SGD","LU0882574055.USD","LU1064131342.USD","LU2213496289.HKD","LU2471134879.HKD","LU0417517546.SGD","LU1069344957.HKD","LU2237443978.SGD","LU2746668974.SGD","THNR","LLYZ","SG9999001176.SGD","SG9999014898.SGD","BK4599","SG9999014906.USD","LU2112291526.USD","LU0096364046.USD","LU1023059063.AUD","LU2264538146.SGD","LU1035775433.USD","GB00BDT5M118.USD","LU2265009873.SGD","LU2108987350.USD","LU2462157665.USD","LU2491050071.SGD","LU2023250330.USD","LU2417539215.USD","SG9999014880.SGD","SG9999014914.USD","OZEM","LU2237443895.HKD","LU2756315664.SGD","LU2063271972.USD","LU0158827948.USD","PSIL","LU2237443382.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU1917777945.USD","LU1551013425.SGD","LU1280957306.USD","LU1720051108.HKD","LU1868836757.USD","CANC","SG9999001176.USD","LU0466842654.USD","IE0009355771.USD","LLYX","LU2271345857.HKD","LU2602419157.SGD","IE00B2B36J28.USD","LU1323610961.USD","LU1720051017.SGD","IE00BFSS8Q28.SGD","LU2089283258.USD","SGXZ99366536.SGD","IE00BKDWB100.SGD","LU0109394709.USD","LU1989771016.USD","LU2089284900.SGD","BK4534","LU1145028129.USD","LU2462591350.SGD","LU0354030511.USD","LU0823434583.USD","LU1974910355.USD","TRUH","IE0001KFT4U8.USD","MEDX","LU0256863902.USD","LU0345770993.USD","LU1868837300.USD","LU0354030438.USD","LU2357305700.SGD","LU0964807845.USD","LU0385154629.USD","LU0266013472.USD","SGXZ81514606.USD","FHLC","LU0708995401.HKD","BK4139","LU0353189680.USD","LU0889565916.HKD","LU1988902786.USD","LU2746668461.USD","LU1979441026.SGD","LU0683600562.USD","LU2028103732.USD","LU2552382215.SGD","IE00B4JS1V06.HKD","SGXZ51526630.SGD","LU1366192091.USD","JDOC","LU2750360641.GBP","LU0061475181.USD","IE00B1BXHZ80.USD","IHE","LU0432979614.USD","SG9999013999.USD","BK4007","LU0820561909.HKD","LU2360106947.USD","LU0122379950.USD","BK4581","IE00B775H168.HKD","IE0002141913.USD","LU1629891620.HKD","LU2361045086.USD","LU2471134952.CNY","IE0004445015.USD","SG9999015986.USD","LU0174119429.USD","IE0004445239.USD","BK4588","ELIS","LU1057294990.SGD","LU2089984988.USD","LU2461242641.AUD","BK4533","IE00BKPKM429.USD","LU0225283273.USD","LU0787776722.HKD","LU0256863811.USD","LU0471298694.HKD","LU2237443549.SGD","LU0471298777.SGD","LU2168564065.EUR","LU2023251221.USD","LU1983299246.USD","LU2237443622.USD","LU2106854487.HKD","LU0456855351.SGD","LU0786609619.USD","IE00BJJMRX11.SGD","CURE","LLII","LU0109391861.USD","LLY","LU0158827781.USD","LU1232071149.USD","LU1551013342.USD","LU2237438978.USD","LU2750360997.AUD","SGXZ31699556.SGD","BK4516","IE00BFSS7M15.SGD","IE00BJJMRZ35.SGD","LU1267930730.SGD","PPH","SG9999018857.SGD","XLV","LU1712237335.SGD","LU0820561818.USD","LU2111349929.HKD","LU0823416689.USD","LU2361044949.HKD","LU2237443465.HKD","LU0210536198.USD","LU0006306889.USD","LU0353189763.USD","LU2023250504.SGD","LU1127390331.HKD","SG9999015945.SGD","LU1548497426.USD","LU1061106388.HKD","RXL","MEDI","VHT","LU2168563687.JPY","PSCH","LU0058720904.USD","IE00BWXC8680.SGD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657656597","title":"Corcept Therapeutics (CORT) Stock Could Be Undervalued Despite Mixed Broader Checks","url":"https://stock-news.laohu8.com/highlight/detail?id=2657656597","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657656597?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:39","pubTimestamp":1786030757,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics stock has delivered a very large 5 year return, yet its recent valuation checks suggest the shares are not an obvious bargain at today's level.\n\nOver the past 5 years, Corcept Therapeutics has returned about 4.4x, which sets a high bar for any further upside to be justified by fundamentals.\nInvestor focus is currently on how demand for the company’s treatments and late stage pipeline can support future revenue, while execution and clinical outcomes across those programs...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/corcept-therapeutics-cort-stock-could-be-undervalued-despite","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/corcept-therapeutics-cort-stock-could-be-undervalued-despite","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4532","CORT","PSCH","FBT","BK4007","LU0566484027.USD","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657572786","title":"Takeda Wins First-in-Class U.S. Approval for Orexin Therapy in Narcolepsy Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2657572786","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657572786?lang=en_us&edition=fundamental","pubTime":"2026-08-06 07:25","pubTimestamp":1785972320,"startTime":"0","endTime":"0","summary":"The latest update is out from Takeda Pharmaceutical Co ( ($JP:4502) ). Takeda has secured U.S. FDA approval for ORZEYFUL, an oral orexin receptor 2...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takeda-wins-first-in-class-u-s-approval-for-orexin-therapy-in-narcolepsy-type-1?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takeda-wins-first-in-class-u-s-approval-for-orexin-therapy-in-narcolepsy-type-1?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNX","MRNY","IBB","IYH","BK4585","TECB","PINK","IDNA","SYNB","RSPH","TBXU","GDOC","MEDI","LABU","BK4588","PSCH","BMED","GNMX","LFSC","XLVX","FRTY","BBP","IEIH","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657571260","title":"Corcept Chief Accounting & Technology Officer Joseph Douglas Lyon Disposes of 1,540 Common Shares Worth $175,806.40","url":"https://stock-news.laohu8.com/highlight/detail?id=2657571260","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657571260?lang=en_us&edition=fundamental","pubTime":"2026-08-06 06:11","pubTimestamp":1785967865,"startTime":"0","endTime":"0","summary":"Corcept Chief Accounting & Technology Officer Joseph Douglas Lyon disposes of 1,540 common shares worth $175,806.40Corcept Therapeutics Chief Accounting & Technology Officer Joseph Douglas Lyon sold 1","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL4ffvrh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Chief Accounting & Technology Officer Joseph Douglas Lyon Disposes of 1,540 Common Shares Worth $175,806.40","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","FBT","LU0566484027.USD","PSCH","BK4532","LU1559883803.SGD","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657208075","title":"Arcutis Q2 Revenue Rises on Demand for Zoryve, Lifts 2026 Sales Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657208075","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657208075?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:08","pubTimestamp":1785960518,"startTime":"0","endTime":"0","summary":"Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlookOverviewUS dermatology drug maker's Q2 product revenue rose 59% yr/yr, driven by ZORYVE demandCompany raised 2026 full-year net p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421A9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACAD","ARQT","BK4139","HELX","LU2065171402.SGD","LU2065171311.SGD","SNDX","KRYS","LU2065169927.USD","LU2065170008.USD","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657543991","title":"United Therapeutics Q2 Revenue Misses Estimates on Ebulized Tyvaso Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2657543991","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657543991?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:38","pubTimestamp":1785926324,"startTime":"0","endTime":"0","summary":"United Therapeutics Q2 revenue misses estimates on Ebulized Tyvaso weaknessOverviewRare disease drugmaker's Q2 revenue fell 2% yr/yr, missing analyst expectationsQ2 net income rose 8% yr/yr; diluted E","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4420FK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","HELX","PSCH","LU1699723380.USD","KRYS","TVTX","UTHR","BK4139","LFSC","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657404561","title":"Ultragenyx Q2 Revenue Rises 28% to Record High, Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2657404561","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657404561?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:18","pubTimestamp":1785874711,"startTime":"0","endTime":"0","summary":"Ultragenyx Q2 revenue rises 28% to record high, net loss narrowsOverviewUS biopharma for rare diseases reported Q2 revenue up yr/yr to highest in company historyNet loss for Q2 narrowed yr/yr, with lo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N441167:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRMY","MEDI","RYTM","BK4139","PSCH","KRYS","BK4585","BK4007","HELX","RARE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656300056","title":"Alkermes EVP, CLO David Joseph Gaffin Sells 2,034 Shares for $98,821.72","url":"https://stock-news.laohu8.com/highlight/detail?id=2656300056","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656300056?lang=en_us&edition=fundamental","pubTime":"2026-08-04 07:10","pubTimestamp":1785798604,"startTime":"0","endTime":"0","summary":"Alkermes EVP, CLO David Joseph Gaffin sells 2,034 shares for $98,821.72David Joseph Gaffin, EVP and chief legal officer, sold 2,034 ordinary shares on Aug. 3, 2026 at USD 48.58.His direct stake fell t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL9zXC08:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes EVP, CLO David Joseph Gaffin Sells 2,034 Shares for $98,821.72","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS","BK4139","PSCH","FBT","PSIL","MEDX","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656304023","title":"Corcept CFO Atabak Mokari Sells 79,000 Shares Worth $8.95 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2656304023","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656304023?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:40","pubTimestamp":1785789635,"startTime":"0","endTime":"0","summary":"Corcept CFO Atabak Mokari sells 79,000 shares worth $8.95 millionCorcept Therapeutics CFO Atabak Mokari exercised stock options for 80,000 shares at USD 23.06 on July 30, 2026.He sold 79,870 shares th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL58BTGS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept CFO Atabak Mokari Sells 79,000 Shares Worth $8.95 Million","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","FBT","LU1559883803.SGD","CORT","PSCH","BK4007","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656304376","title":"Fresenius announces FDA approval of rituximab biosimilar","url":"https://stock-news.laohu8.com/highlight/detail?id=2656304376","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656304376?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:15","pubTimestamp":1785788150,"startTime":"0","endTime":"0","summary":"Fresenius Kabi, an operating company of Fresenius (FSNUY), announced that the U.S. Food and Drug Administration has approved a rituximab biosimilar...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fresenius-announces-fda-approval-of-rituximab-biosimilar-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fresenius-announces-fda-approval-of-rituximab-biosimilar-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IEIH","GNMX","MRNX","MEDI","IYH","LFSC","TBXU","TECB","SYNB","IDNA","MRNY","NVIB","BK4588","BK4585","BMED","GDOC","PSCH","FRTY","IBB","BBP","XLVX","RSPH","PINK","FSNUY","LABU","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656083301","title":"ClearPoint Neuro Q2 Revenue Rises 18% but Misses Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2656083301","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656083301?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:14","pubTimestamp":1785788065,"startTime":"0","endTime":"0","summary":"ClearPoint Neuro Q2 revenue rises 18% but misses estimatesOverviewDevice and gene therapy-enabling firm's Q2 revenue rose 18% yr/yr but missed analyst expectationsGross margin improved to 62% from 60%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL1N4400ZX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","CLPT","KRYS","PSCH","HELX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656301205","title":"GeneDx Q2 Revenue Beats Analyst Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2656301205","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656301205?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:12","pubTimestamp":1785787943,"startTime":"0","endTime":"0","summary":"GeneDx Q2 revenue beats analyst estimatesOverviewU.S. rare disease genomics tester's Q2 revenue grew 11% yr/yr, beating analyst expectationsAdjusted net income was $0.4 mln, up from a loss in the prio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL1N4400Z6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4196","WGS","PSCH","KRYS","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656019363","title":"Alkermes Amends 8-K to Disclose CEO Blair Jackson Pay Package Including $5 Million Equity Award","url":"https://stock-news.laohu8.com/highlight/detail?id=2656019363","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656019363?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:09","pubTimestamp":1785787780,"startTime":"0","endTime":"0","summary":"Alkermes amends 8-K to disclose CEO Blair Jackson pay package including $5 million equity awardAlkermes amended a Feb. 25 Form 8-K on its CEO succession to add previously undetermined compensation ter","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL2dlwWm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","BK4139","ALKS","PSIL","FBT","MEDX","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656303023","title":"Krystal Biotech Down Nearly 12%, on Pace for Largest Percent Decrease Since August 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2656303023","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656303023?lang=en_us&edition=fundamental","pubTime":"2026-08-04 01:25","pubTimestamp":1785777900,"startTime":"0","endTime":"0","summary":"Krystal Biotech, Inc.  is currently at $300.76, down $40.37 or 11.83%--Would be lowest close since June 2, 2026, when it closed at $293.21--On pace for largest percent decrease since Aug. 4, 2025, when it fell 14.04%--Currently down three of the past four days--Currently down two consecutive days; down 18.02% over this period--Worst two day stretch since the two days ending May 9, 2022, when it fell 21.35%--Up 21.99% year-to-date--Down 20.47% from its all-time closing high of $378.15 on June 29, 2026--Up 122.88% from 52 weeks ago , when it closed at $134.94--Down 20.47% from its 52-week closing high of $378.15 on June 29, 2026--Up 122.88% from its 52-week closing low of $134.94 on Aug. 4, 2025--Traded as low as $297.02; lowest intraday level since June 3, 2026, when it hit $290.04--Down 12.93% at today's intraday low; largest intraday percent decrease since Aug. 4, 2025, when it fell as much as 16.87%All data as of 1:20:00 PM ETSource: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","BK4585","XBI","HELX","BK4139","BK4581","BK4588","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656330819","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2656330819","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656330819?lang=en_us&edition=fundamental","pubTime":"2026-08-04 00:00","pubTimestamp":1785772852,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Opus Genetics (IRD) and Krystal Biotech (KRYS) with ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-271?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-271?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRD","BK4139","BK4007","HELX","PSCH","KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656648372","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2656648372","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656648372?lang=en_us&edition=fundamental","pubTime":"2026-08-03 21:50","pubTimestamp":1785765023,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BrightSpring Health Services, Inc. (BTSG), Monte Ros...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-270?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-270?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BTSG","BK4196","LU2468319806.SGD","PTH","LU2089984988.USD","PSCH","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656374922","title":"Krystal Biotech Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2656374922","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656374922?lang=en_us&edition=fundamental","pubTime":"2026-08-03 21:31","pubTimestamp":1785763905,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc reports results for the quarter ended June 30 - Earnings SummaryKrystal Biotech IncKRYS.OQreported quarterly adjusted earnings of $1.79 per share for the quarter ended June 30, hig","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL8N4401GJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HELX","PSCH","KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656866379","title":"Design Therapeutics Q2 Net Loss Narrower than Expected","url":"https://stock-news.laohu8.com/highlight/detail?id=2656866379","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656866379?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:15","pubTimestamp":1785759346,"startTime":"0","endTime":"0","summary":"Design Therapeutics Q2 net loss narrower than expectedOverviewUS biotech firm's Q2 net loss was lower than analyst expectationsOperating expenses for Q2 totaled $22.2 mlnCompany ended Q2 with $207.4 m","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL1N4400FA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGTX","KRYS","BK4007","OCUL","PSCH","BK4585","BK4588","HELX","DSGN","BK4139","BK4539","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656375311","title":"Ocular Therapeutix Q2 Product Revenue Flat, Net Loss Widens on Higher Spending","url":"https://stock-news.laohu8.com/highlight/detail?id=2656375311","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656375311?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:21","pubTimestamp":1785756090,"startTime":"0","endTime":"0","summary":"Ocular Therapeutix Q2 product revenue flat, net loss widens on higher spendingOverviewUS biopharmaceutical firm's Q2 product revenue was flat yr/yrNet loss for Q2 widened compared to prior yearCompany","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL1N4400DI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","OCUL","IDNA","LGHT","BK4532","BK4533","MRNX","HELX","BK4585","KRYS","WDNA","BK4139","MRNY","BK4501","BK4551","BK4548","MRNA","BK4588","TGTX","BK4534","BK4568","GNOM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}